JPWO2021247969A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021247969A5
JPWO2021247969A5 JP2022574753A JP2022574753A JPWO2021247969A5 JP WO2021247969 A5 JPWO2021247969 A5 JP WO2021247969A5 JP 2022574753 A JP2022574753 A JP 2022574753A JP 2022574753 A JP2022574753 A JP 2022574753A JP WO2021247969 A5 JPWO2021247969 A5 JP WO2021247969A5
Authority
JP
Japan
Prior art keywords
carboxamide
pyrazole
ethynyl
pyrrolidin
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574753A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529867A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/035854 external-priority patent/WO2021247969A1/en
Publication of JP2023529867A publication Critical patent/JP2023529867A/ja
Publication of JPWO2021247969A5 publication Critical patent/JPWO2021247969A5/ja
Pending legal-status Critical Current

Links

JP2022574753A 2020-06-05 2021-06-04 線維芽細胞増殖因子受容体キナーゼの阻害剤 Pending JP2023529867A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063035155P 2020-06-05 2020-06-05
US63/035,155 2020-06-05
US202063106812P 2020-10-28 2020-10-28
US63/106,812 2020-10-28
PCT/US2021/035854 WO2021247969A1 (en) 2020-06-05 2021-06-04 Inhibitors of fibroblast growth factor receptor kinases

Publications (2)

Publication Number Publication Date
JP2023529867A JP2023529867A (ja) 2023-07-12
JPWO2021247969A5 true JPWO2021247969A5 (ru) 2024-06-11

Family

ID=78829924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022574753A Pending JP2023529867A (ja) 2020-06-05 2021-06-04 線維芽細胞増殖因子受容体キナーゼの阻害剤

Country Status (14)

Country Link
US (2) US11345681B1 (ru)
EP (1) EP4161656A4 (ru)
JP (1) JP2023529867A (ru)
KR (1) KR20230035031A (ru)
CN (1) CN116057045A (ru)
AU (1) AU2021282596A1 (ru)
BR (1) BR112022024729A2 (ru)
CA (1) CA3181162A1 (ru)
CL (1) CL2022003427A1 (ru)
CO (1) CO2022018806A2 (ru)
IL (1) IL298760A (ru)
MX (1) MX2022015410A (ru)
TW (1) TW202210472A (ru)
WO (1) WO2021247969A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4161656A4 (en) 2020-06-05 2024-06-19 Kinnate Biopharma Inc. INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
CN116685582A (zh) * 2021-01-12 2023-09-01 北京诺诚健华医药科技有限公司 (s)-1-(1-丙烯酰吡咯烷-3-基)-3-((3,5-二甲氧苯基)乙炔基)-5-(甲基氨基)-1h-吡唑-4-甲酰胺的制备工艺
WO2023107870A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
WO2023107980A1 (en) * 2021-12-08 2023-06-15 Kinnate Biopharma Inc. Solid state forms of an fgfr inhibitor
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor
CN115232074A (zh) * 2022-08-22 2022-10-25 湖南复瑞生物医药技术有限责任公司 一种1-烷基取代-2-甲基-5-溴苯并咪唑的合成方法

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5886022A (en) 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
SI9600371B (sl) 1996-12-18 2005-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Etilidenski derivati tricikličnih karbapenemov
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ グループ リミテッド Hcv阻害剤としての4−(5−員)−ヘテロアリールアシルピロリジン誘導体
ES2289161T3 (es) 2001-11-02 2008-02-01 Glaxo Group Limited Derivados de 4-(heteroaril de 6 miembros)-acil pirrolidina como inhibidores de hcv.
JP4749715B2 (ja) 2002-07-05 2011-08-17 ターガセプト,インコーポレイテッド N−アリールジアザスピロ環式化合物、並びにその製造及び使用方法
US7754188B2 (en) 2003-06-30 2010-07-13 Merck Sharp & Dohme Corp. Radiolabeled cannabinoid-1 receptor modulators
FR2860431A1 (fr) 2003-10-02 2005-04-08 Oreal Composition capillaire ou de mascara contenant un compose azoique, son utilisation pour stimuler ou induire la pousse des cheveux ou des cils et/ou freiner leur chute
CN1882347A (zh) 2003-11-21 2006-12-20 阿雷生物药品公司 Akt蛋白激酶抑制剂
US20080004263A1 (en) 2004-03-04 2008-01-03 Santora Vincent J Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof
EP1740587A4 (en) 2004-04-02 2009-07-15 Adenosine Therapeutics Llc SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
AU2005277410B2 (en) 2004-08-20 2010-06-24 Targacept, Inc. The use of N-aryl diazaspiracyclic compounds in the treatment of addiction
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2007024814A1 (en) 2005-08-22 2007-03-01 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CN103214483B (zh) 2005-12-13 2014-12-17 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
WO2007087283A2 (en) 2006-01-23 2007-08-02 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
US7829590B2 (en) 2006-04-13 2010-11-09 Guy Brenchley Thiophene-carboxamides useful as inhibitors of protein kinases
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
AU2007268056A1 (en) 2006-05-23 2007-12-06 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP2027116A2 (en) 2006-05-23 2009-02-25 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
US7989458B2 (en) 2006-07-14 2011-08-02 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
EP2049548A1 (en) 2006-07-27 2009-04-22 UCB Pharma, S.A. Fused oxazoles & thiazoles as histamine h3- receptor ligands
KR101491998B1 (ko) 2006-12-28 2015-02-10 애브비 인코포레이티드 폴리(adp-리보스)폴리머라제 억제제
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
EP2036906A1 (de) 2007-09-05 2009-03-18 Bayer Schering Pharma Aktiengesellschaft Azaindole als Inhibitoren der löslichen Adenylatzyklase
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
NZ586399A (en) 2008-01-24 2011-12-22 Ucb Pharma Sa Compounds comprising a cyclobutoxy group
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
EP2401273A1 (en) 2009-02-27 2012-01-04 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550278A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011119858A1 (en) 2010-03-24 2011-09-29 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
SG186378A1 (en) 2010-06-23 2013-01-30 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012116135A2 (en) 2011-02-24 2012-08-30 Emory University Noggin blocking compositions for ossification and methods related thereto
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
WO2012154608A1 (en) 2011-05-06 2012-11-15 Intellikine, Llc Reactive mtor and pi3 kinase inhibitors and uses thereof
WO2013025484A1 (en) 2011-08-12 2013-02-21 Lapchak Paul A Polyphenol analogs to treat ischemia
EP2741609A4 (en) 2011-08-12 2015-04-08 Salk Inst For Biological Studi NEUROPROTECTIVE POLYPHENOLANALOGA
CN103889982A (zh) 2011-10-18 2014-06-25 先正达参股股份有限公司 杀微生物的吡唑衍生物
GB201119799D0 (en) 2011-11-16 2011-12-28 Sentinel Oncology Ltd Pharmaceutical compounds
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
EP2615083A1 (en) 2012-01-10 2013-07-17 Studiengesellschaft Kohle mbH Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN104350057A (zh) 2012-04-12 2015-02-11 泽农医药公司 用作治疗剂的螺-羟吲哚化合物的不对称合成
WO2013170118A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Thiazolecarboxamide derivatives for use as nampt inhibitors
CN104684906B (zh) 2012-05-11 2017-06-09 艾伯维公司 Nampt抑制剂
US8975398B2 (en) 2012-05-11 2015-03-10 Abbvie Inc. NAMPT inhibitors
IN2015DN02008A (ru) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
WO2014158943A1 (en) 2013-03-13 2014-10-02 Avon Products, Inc Tyrosinase inhibitors
US20160008493A1 (en) 2013-03-15 2016-01-14 The Johns Hopkins University Radioactive substrates for aldehyde dehydrogenase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
WO2014190096A1 (en) 2013-05-22 2014-11-27 Curza Global, Llc Compositions and methods comprising a polyamine
CN105555785B (zh) 2013-06-18 2019-03-01 4Sc股份公司 作为dyrk激酶抑制剂的2,3-二氢苯并呋喃-5-基化合物
WO2014210456A1 (en) 2013-06-28 2014-12-31 Emory University Pyrazoline dihydroquinolones, pharmaceutical compositions, and uses
EP3013798B1 (en) 2013-06-28 2018-06-27 BeiGene, Ltd. Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
TWI574691B (zh) 2013-07-18 2017-03-21 Taiho Pharmaceutical Co Ltd Anti - tumor agents for intermittent administration of FGFR inhibitors
WO2015008844A1 (ja) * 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
JP2016529241A (ja) 2013-07-25 2016-09-23 フォンダッツィオーネ・テレソン Fapp2阻害剤及びそれらの使用
CN104341425B (zh) * 2013-08-08 2018-11-02 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
CA2922341C (en) 2013-08-28 2022-06-07 Vanderbilt University Substituted indole mcl-1 inhibitors
CN104262328B (zh) 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
EP3048105A4 (en) 2013-09-18 2017-05-17 Beijing Hanmi Pharmaceutical Co., Ltd. Compound inhibiting activities of btk and/or jak3 kinases
CN105979948A (zh) 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
WO2015134357A1 (en) 2014-03-03 2015-09-11 Emory University Modulators of insulin receptor
CN112898308A (zh) 2014-08-15 2021-06-04 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2016044445A2 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2016055028A1 (en) 2014-10-10 2016-04-14 Genentech, Inc. Therapeutic compounds and uses thereof
JP6659703B2 (ja) 2015-01-09 2020-03-04 ジェネンテック, インコーポレイテッド ピリダジノン誘導体および癌の処置におけるそれらの使用
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US11476426B2 (en) 2016-02-03 2022-10-18 Sfc Co., Ltd. Organic light emitting compounds and organic light emitting devices including the same
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2018054365A1 (en) 2016-09-24 2018-03-29 Beigene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
JP2019534260A (ja) 2016-10-07 2019-11-28 アラクセス ファーマ エルエルシー Rasの阻害剤としての複素環式化合物およびその使用方法
CN110139865B (zh) * 2016-12-29 2022-02-18 石药集团中奇制药技术(石家庄)有限公司 Fgfr抑制剂
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US20200385364A1 (en) 2017-01-26 2020-12-10 Araxes Pharma Llc Fused n-heterocyclic compounds and methods of use thereof
US10450303B2 (en) 2017-03-15 2019-10-22 Athenex, Inc. Biaryl piperidine amide compounds and methods of use thereof
CN108623562A (zh) 2017-03-24 2018-10-09 中国海洋大学 一种喹啉酮生物碱类化合物及其制备方法和应用
CN108658972A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种取代内酰胺类化合物及其制备方法和用途
CN108658974A (zh) 2017-03-28 2018-10-16 中国海洋大学 一种内酰胺类化合物及其制备方法和用途
CN108690016B (zh) 2017-04-11 2022-08-12 广东东阳光药业有限公司 吡唑并吡啶类化合物及其用途
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019023448A1 (en) 2017-07-26 2019-01-31 Emory University INHIBITORS OF NADPH OXIDASE AND THEIR USE
CN111093773A (zh) 2017-08-15 2020-05-01 英夫拉索姆有限公司 作为nlrp3抑制剂的磺酰脲和磺酰硫脲
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CN110117285B (zh) 2018-02-07 2023-02-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
EP3774798A1 (en) 2018-04-02 2021-02-17 Silverback Therapeutics, Inc. Alk5 inhibitors, conjugates, and uses thereof
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
TW202021969A (zh) 2018-05-31 2020-06-16 南韓商C&C新藥研究所 雜環衍生物及其用途
WO2019238067A1 (en) 2018-06-13 2019-12-19 Beigene, Ltd. Pyrrolo [2, 3-b] pyridines or pyrrolo [2, 3-b] pyrazines as hpk1 inhibitor and the use thereof
AU2019312670A1 (en) 2018-08-01 2021-02-04 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
AU2020278566A1 (en) * 2019-05-17 2021-12-23 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
EP4161656A4 (en) 2020-06-05 2024-06-19 Kinnate Biopharma Inc. INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES
CN116096707A (zh) 2020-06-05 2023-05-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶的抑制剂

Similar Documents

Publication Publication Date Title
JP6510068B2 (ja) 新規なビフェニル化合物又はその塩
KR100854174B1 (ko) Gaba 수용체에 대한 리간드로서의 벤즈이미다졸 및피리딜이미다졸 유도체
RU2410387C2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-c]ПИРИДИН-4-ОН 2-ИНДОЛИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ
JP2017511801A5 (ru)
JP5039268B2 (ja) ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
ES2611588T3 (es) Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
JP5992096B2 (ja) Pde10阻害剤としてのトリアゾロ化合物
HRP20171613T1 (hr) Derivati pirazolopirolidina i njihova primjena u liječenju bolesti
RU2018112230A (ru) Бициклические соединения в качестве ингибиторов atx
HRP20120174T1 (hr) Derivat policikličnog cinamida
HRP20211483T1 (hr) Derivati 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ola i povezani spojevi kao inhibitori prs za liječenje npr. raka
EP3875078A1 (en) Compounds for the treatment of covid-19
RU2007112110A (ru) Производные пирроло[2.3-с] пиридина и способы их получения
JP2015504057A5 (ru)
KR20110039307A (ko) 이미다조피리딘-2-온 유도체
BG106836A (bg) Азаиндоли
JP2017510576A5 (ru)
RU2009125614A (ru) Глюкокортикоидные миметики, способы их получения, фармацевтические композиции и их применения
EA031601B1 (ru) Ингибиторы syk
JP2012528828A5 (ru)
RU2003107016A (ru) Замещенные пиразолы
JP2007526285A5 (ru)
FI3749669T3 (fi) AHR-modulaattoreita
KR20100128305A (ko) C-met 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-b]피리다진 유도체
EA024108B1 (ru) ПРОИЗВОДНЫЕ [1,2,3]ТРИАЗОЛО[4,5-d]ПИРИМИДИНА В КАЧЕСТВЕ АГОНИСТОВ КАННАБИНОИДНОГО РЕЦЕПТОРА 2